Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

KRAS and BRAF mutations in anal carcinoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Primary antibiotic resistance of Helicobacter pylori strains among adults and children in a tertiary referral centre in Lithuania

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A short history of microbial biofilms and biofilm infections

    Research output: Contribution to journalReviewResearchpeer-review

  3. Biofilms and host response - helpful or harmful

    Research output: Contribution to journalReviewResearchpeer-review

  4. Diagnosis of biofilm infections in cystic fibrosis patients

    Research output: Contribution to journalReviewResearchpeer-review

  1. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer

    Research output: Contribution to journalReviewResearchpeer-review

  3. Diffusion MRI outlined viable tumour volume beats GTV in intra-treatment stratification of outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The EGF receptor (EGFR) is expressed in most cases of anal carcinomas. Anecdotal benefit from EGFR-targeted therapy has been reported in anal cancer and a negative correlation with Kirsten Ras (KRAS) mutation status has been proposed. The purpose of this retrospective study was to investigate the frequency and the prognostic value of KRAS and BRAF mutations in a large cohort of patients with anal cancer. One hundred and ninety-three patients with T1-4N0-3M0-1 anal carcinoma were included in the study. Patients were treated with curative (92%) or palliative intent (8%) between January 2000 and January 2010. KRAS mutations were detected using Therascreen(®)KRAS real-time PCR assay (Qiagen) and V600E or V600D/K BRAF mutations were uncovered using Pyrosequencing. The frequency of KRAS and BRAF mutations was low; KRAS mutations were detected in 1.6% and BRAF mutations in 4.7% of the biopsies. No impact of KRAS or BRAF status on survival was found. In conclusion, both KRAS and BRAF mutations are rare in anal cancer. The low frequency of KRAS mutations support protocols exploring EGFR-targeted therapy in patients with metastatic anal cancer, while treatment with BRAF inhibitors might be relevant for only a very few patients.

Original languageEnglish
JournalAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica
Volume123
Issue number1
Pages (from-to)53-9
Number of pages7
ISSN0903-4641
DOIs
Publication statusPublished - Jan 2015

ID: 45090688